



STATE BOARD OF OPTOMETRY
 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834
 P (916) 575-7170 F (916) 575-7292 www.optometry .ca.gov



Continuing Education Course
 Approval Checklist

Title:

Provider Name:

- Completed Application
 - Open to all Optometrists? Yes No
 - Maintain Record Agreement? Yes No
- Correct Application Fee
- Detailed Course Summary
- Detailed Course Outline
- PowerPoint and/or other Presentation Materials
- Advertising (optional)
- CV for EACH Course Instructor
- License Verification for Each Course Instructor
 - Disciplinary History? Yes No



STATE BOARD OF OPTOMETRY
 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834
 P (916) 575-7170 F (916) 575-7292 www.optometry.ca.gov



CONTINUING EDUCATION COURSE APPROVAL APPLICATION

\$50 Mandatory Fee

Pursuant to California Code of Regulations (CCR) § 1536, the Board will approve continuing education (CE) courses after receiving the applicable fee, the requested information below and it has been determined that the course meets criteria specified in CCR § 1536(g).

In addition to the information requested below, please attach a copy of the course schedule, a detailed course outline and presentation materials (e.g., PowerPoint presentation). Applications must be submitted 45 days prior to the course presentation date.

Please type or print clearly.

Course Title Aggressive Retinopathy of prematurity (written + management & practical) considerations	Course Presentation Date <div style="text-align: center; font-size: 1.2em;"> <input type="text" value="1"/> <input type="text" value="1"/> / <input type="text" value="0"/> <input type="text" value="6"/> / <input type="text" value="2"/> <input type="text" value="0"/> <input type="text" value="1"/> <input type="text" value="6"/> </div>
---	---

Course Provider Contact Information

Provider Name		
Lisette (First)	Rosales (Last)	(Middle)

Provider Mailing Address			
Street	4353 Park Terrace Dr #150	City	Westlake Village State CA Zip 91361

Provider Email Address	rosales@daughertylaser vision.com
-------------------------------	-----------------------------------

Will the proposed course be open to all California licensed optometrists?	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
---	---

Do you agree to maintain and furnish to the Board and/or attending licensee such records of course content and attendance as the Board requires, for a period of at least three years from the date of course presentation?	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
---	---

Course Instructor Information

Please provide the information below and attach the curriculum vitae for each instructor or lecturer involved in the course. If there are more instructors in the course, please provide the requested information on a separate sheet of paper.

Instructor Name		
Khaled (First)	Tawansy (Last)	(Middle)

License Number 76762	License Type physician & surgeon
-----------------------------	---

Phone Number (323) 257-3937	Email Address ktawansy@gmail.com
------------------------------------	---

I declare under penalty of perjury under the laws of the State of California that all the information submitted on this form and on any accompanying attachments submitted is true and correct.

 Signature of Course Provider

2-15-17

 Date

Khaled Tawansy, presentation start and end time: 9:00 a.m. -10:00 a.m.= 1 hour

Summary:

Aggressive Retinopathy of prematurity: Current Management and Practical Considerations

The purpose of this talk is to review Retinopathy of prematurity and give background information on this topic. This covers Proliferative retinopathy of premature and low birth-weight infants. This talk also covers treatment options for Ablation, and treatment criteria. It also covers types of ROP laser ablation with photos; variation in laser techniques can impact myopia and field loss in intensity, confluence and location.

- *Aggressive retinopathy of prematurity: Current Management & Practical Considerations*

Dougherty laser vision 10/6/2016

- *Khaled A. Tawansy, M.D.*

- Professor of Ophthalmology & Pediatrics

- Director, Children's Retina Institute of California

- *ktawansy@gmail.com*

- Cell 323-313-5757

- Office 805-497-7976

- Retinopathy of Prematurity

- First recognized by Terry in 1954 as Retrolental Fibroplasia

- Proliferative retinopathy of premature and low birth-weight infants

- 66% of babies under 1250 grams at birth have some manifestations

- Leading cause of blindness in nations that sustain preemies

- 2500 impaired annually in United States

- ROP Screening and early detection are key

- Zone and severity of Plus most important prognostic features

- Stage 3 - Extra-retinal neovascularization with Plus
- ROP Treatment
- Anti-VEGF Therapy
 - Alter Biochemistry
 - Vascular Burden
- Ablation
 - Alter Topography
 - Vascular Burden
 - Non-Perfusion
- Treatment Criteria for Ablation in Neonatal ROP
- Cryo-ROP defined Threshold for Ablation
 - 5 contiguous or 8 cumulative clock hrs of stage 3 in zones I and II
 - Outcomes not as favorable in zone I
- ET-ROP defined Pre-Threshold types 1 and 2
- Type 1 (ablation recommended)
 - Zone I any stage 3
 - Zone I stage 1 & 2 with plus
 - Zone II stage 2 and 3 with plus
- Type 2
 - Any ROP below type 1
- Treatment Criteria for Anti-VEGF in Neonatal ROP
- BEAT-ROP

- Stage 3 plus in Zone I and Posterior Zone II
 - Within 3 x disc to fovea radius
 - Most posterior meridian counts
- Number of clock hours not criteria
- Virgin (non-ablated) eyes
- Disease allowed to advance beyond ET-ROP criteria for ablation
- Randomization of Avastin vs. Ablation

■ (Potential) **Advantages** of Anti-VEGF

1) Lower recurrence rate?

- In BEAT-ROP at 54 weeks, recurrence in
 - 32 of 146 laser eyes (22%)
 - 6 of 139 avastin eyes (4%)
- Problem
 - Recurrence after laser unacceptably high
(Under 1 % in Children's Retina Inst. series)
 - Recurrence after avastin occurs beyond 54 weeks
(Has occurred years after avastin)

■ (Potential) **Advantages** of Anti-VEGF

2) Preservation of field

- Ablation posterior to the equator will compromise

3) Prevention of myopia

- Especially when mono-therapy done early

4) Immediate reversal of plus and ischemia

- 24 hours versus 2 weeks

5) Less traumatic procedure

- Better tolerated by fragile preemies

6) Does not require clear media or attached retina

- Before & 24 hours post Avastin
- Tunica Vasculosa Lentis pre and post bevacizumab injection

- (Potential) **Disadvantages** of Anti-VEGF

1) Systemic toxicity

- Hard to disprove
- Not seen with 0.625 mg dose in unablated eyes

2) Cataract

- Surgical disaster, high rate of re proliferation
- Technique is important, needle directed peripherally
- Safer to perforate unvascularized retina than to hit lens

3) Crunch (fibrovascular contraction)

- Not seen if treatment done on time
- Will accelerate existing traction
- Anticipate vitrectomy

- Avastin Crunch

- (Potential) **Disadvantages** of Anti-VEGF

4) Arrest of Intrinsic Vascular Development

- Hell freezes over
- Not selective to neovascularization
- Persistent peripheral non-perfusion
- "Smoldering ROP" or "FEVR-Like"

- Can develop late recurrence, traction, macular dragging, late detachment
 - Can occur any time, need to be followed until mature
 - **Marriage** to patient and the parents
 - Potential disasters if they fail to follow up
 - May need to laser later anyhow

- ROP – Regression post Anti-VEGF

- 24 weeks gestation, avastin at 35 weeks, retinal detachment at 65 weeks

- (Potential) Advantages of Laser Ablation

- Thirty years of follow up
 - Good visual function
 - Absence of systemic complications

- The BEST procedure in medicine
 - Based on cost / benefit analysis using QUALYs
 - Reliable and effective

- Put the disease to bed
 - Not as concerned if follow up missed

- Easier to titrate the extent of treatment or perform focal treatment

- Potential long-term benefits of ablation
 - ? Lower rate of late retinal detachment

- ROP – Ablative Treatment

- Aggressive ROP, what are the options?
- Observation

- Systemic Medical Management

- Laser Ablation

- Anti-VEGF

- Laser Ablation and Anti-VEGF

- Type 1 ROP, why observe?
- ET-ROP showed lower rate of late complications at the expense of many additional laser procedures (5 unnecessary treatments for every necessary treatment)

- ET-ROP gives guidelines but not absolute indications for treatment

- Anti-VEGF was not available during ET-ROP, gives opportunity to reverse accelerating cases

- Need judgment, assess vascular burden

- May choose to **closely** follow patients with stage 2/3 plus or stage 3 without plus

- Type 1 ROP, Systemic Management?

- Remember STOP-ROP
 - Lower progression to threshold in stage III plus
- Experience at Stanford (M. Gannon)
- O₂ supplementation to keep saturation > 98%
- Transfusion to keep hematocrit at 40%
- Avoid Erythropoietin
- Type 1 ROP, Laser Ablation
- Typical ROP and Smoldering ROP
- Anterior to equator
- Tractional component > Vascular component
- Delayed vascular maturation
- Parents unreliable for follow up
- At Children's Retina Institute, 70% of primary therapy since BEAT-ROP is ablation
- Low vascularity, evolving traction
- Type 1 ROP, Laser Ablation

- Variation in laser techniques can impact myopia and field loss
 - Intensity
 - Confluence
 - Location

- Type 1 ROP, Anti-VEGF Rx
- Avastin is agent of choice
 - Cost
 - Lowest penetrance of blood-retinal barrier
 - Experience

- Dose has not been adequately defined
 - 0.625 mg in BEAT-ROP
 - Lower doses may suppress vascular activity without inhibiting intrinsic vascular development

- Type 1 ROP, Anti-VEGF Rx
- High vascular activity and posterior disease

- Too fragile to tolerate laser procedure

- Media opacity: vitreous heme, cataract, tunica vasculosa lentis

- Retina detached, anticipating vitrectomy

- Long term commitment to follow up

- Laser not available
- Type 1 ROP, Anti-VEGF Rx:
Follow up Protocol p Injection
- Office every 2 weeks examining leading edge of vascular development
- 70 % will reach the ora serrata
- 30% will remain non-perfused peripherally
- Fluorescein helps to define regression pattern
 - Blind ending vessels
 - Horse hair supernumerous vessels with dilation
 - Smoldering ridge with leakage
 - Traction with macular dragging, retinal detachment
- Silent Brush Border
- Avastin: 830 grams; 26 wk gestation, injection at 2 month and still non-perfused at 20 mo
- 550 gm; 22 wk gestation
- (Avastin Failure)
- Recurrence post Avastin
- Type 1 ROP, Anti-VEGF Rx:
Follow up Protocol p Injection

- Eyes that do not fully vascularize by 70 weeks post conception are not likely to ever fully vascularize
 - Examination under anesthesia with fluorescein angiogram performed at the preemie's first birthday
 - Residual avascular retina is ablated
 - Judging Vascular Disease Burden
 - No substitute for clinical experience
 - Vascular Activity Score
 - Grading system using parameters that we typically use to judge degree of activity
 - Correlates linearly with anatomic failure during PPV for ROP retinal detachment
 - Guides Avastin therapy
 - Vascular Activity Score:
 - 5 categories
 - Fetal Vessels
 - Plus
 - Shunt Width
 - Neovascularization
 - Hemorrhage or exudate
- 0-2 points for each category**
10 possible points

- 26 weeks gestation, 34 weeks PCA
Wide ridge and 360 degrees NV & significant plus & exudate
- Relationship between vascular activity score and anatomic outcome with vitrectomy
- Combined Anti-VEGF & Laser Ablation
- Rarely done in severe cases
 - Missed screening
 - ROP plus
 - FEVR / Norrin / I.P. mutation
 - Systemic hemangioma
 - Bone marrow diseases
 - Vasculitis
- Cannot wait for VEGF levels to drop w ablation
- Only opportunity to treat
- Prefer give Anti-VEGF first, ablation after 1-2 days

- Comment: Anti-VEGF vs Laser Ablation in Type 1 ROP
- Metabolic versus Anatomic Manipulation
- Laser Ablation remains the mainstay of ROP management
- Anti-VEGF is an important adjunctive tool that has allowed excellent outcomes in eyes with previously limited prognosis, posterior and vascularly aggressive
- Proposed guidelines can not replace clinical experience and judgment, Vascular Activity Score can help
- Follow up and Fluorescein Angiography are **Crucial** after Anti-VEGF

AGGRESSIVE RETINOPATHY OF PREMATURITY; CURRENT MANAGEMENT & PRACTICAL CONSIDERATIONS

DOUGHERTY LASER VISION 10/6/2016

Khaled A. Tawansy, M.D.

Professor of Ophthalmology & Pediatrics
Director, Children's Retina Institute of California
Thousand Oaks, Pasadena, Bakersfield, Long Beach
ktawansy@gmail.com
Cell 323-313-5757

ROP Treatment

- Anti-VEGF Therapy
 - Alter Biochemistry
 - Vascular Burden
- Ablation
 - Alter Topography
 - Vascular Burden
 - Non-Perfusion

Treatment Criteria for Ablation in Neonatal ROP

- Cry-ROP defined Threshold for Ablation
 - 5 contiguous or 8 cumulative clock hrs of stage 3 in zones I and II
 - Outcomes not as favorable in zone I
- ET-ROP defined Pre-Threshold types 1 and 2
- Type 1 (ablation recommended)
 - Zone I any stage 3
 - Zone I stage 1 & 2 with plus
 - Zone II stage 2 and 3 with plus
- Type 2
 - Any ROP below type 1

Treatment Criteria for Anti- VEGF in Neonatal ROP







- BEAT-ROP
 - Stage 3 plus in Zone I and Posterior Zone II
 - Within 3 x disc to fovea radius
 - Most posterior meridian counts
 - Number of clock hours not criteria
 - Virgin (non-ablated) eyes
 - Disease allowed to advance beyond ET-ROP criteria for ablation
 - Randomization of Avastin vs. Ablation



(Potential) Advantages of Anti- VEGF

- 1) Lower recurrence rate?
 - In BEAT-ROP at 54 weeks, recurrence in
 - 32 of 146 laser eyes (22%)
 - 6 of 139 avastin eyes (4%)
 - Problem
 - Recurrence after laser unacceptably high
(Under 1 % in Children's Retina Inst. series)
 - Recurrence after avastin occurs beyond 54 weeks
(Has occurred years after avastin)


(Potential) Advantages of Anti- VEGF

- 2) Preservation of field
 - Ablation posterior to the equator will compromise
- 3) Prevention of myopia
 - Especially when mono-therapy done early
- 4) Immediate reversal of plus and ischemia
 - 24 hours versus 2 weeks
- 5) Less traumatic procedure
 - Better tolerated by fragile preemies
- 6) Does not require clear media or attached retina






- (Potential) Advantages of Laser Ablation
1. Thirty years of follow up
 - o Good visual function
 - o Absence of systemic complications
 2. The BEST procedure in medicine
 - o Based on cost / benefit analysis using QALYs
 - o Reliable and effective
 3. Put the disease to bed
 - o Not as concerned if follow up missed
 4. Easier to titrate the extent of treatment or perform focal treatment
 5. Potential long-term benefits of ablation
 - o ? Lower rate of late retinal detachment



- Type 1 ROP, what are the options?
- Observation
 - Systemic Medical Management
 - Laser Ablation
 - Anti-VEGF
 - Laser Ablation and Anti-VEGF

- Type 1 ROP, why observe?
- ET-ROP showed lower rate of late complications at the expense of many additional laser procedures (5 unnecessary treatments for every necessary treatment)
 - ET-ROP gives guidelines but not absolute indications for treatment
 - Anti-VEGF was not available during ET-ROP, gives opportunity to reverse accelerating cases
 - Need judgment, assess vascular burden
 - May choose to **closely** follow patients with stage 2/3 plus or stage 3 without plus




Type 1 ROP, Systemic Management?

- Remember STOP-ROP
 - Lower progression to threshold in stage III plus
- Experience at Stanford (M. Gannon)
- O₂ supplementation to keep saturation > 98%
- Transfusion to keep hematocrit at 40%
- Avoid Erythropoietin

Type 1 ROP, Laser Ablation

- Typical ROP and Smoldering ROP
- Anterior to equator
- Tractional component > Vascular component
- Delayed vascular maturation
- Parents unreliable for follow up
- At Children's Retina Institute, 70% of primary therapy since BEAT-ROP is ablation

Low vascularity, evolving traction



Type 1 ROP, Laser Ablation

- Variation in laser techniques can impact myopia and field loss
 - Intensity
 - Confluence
 - Location

Type 1 ROP, Anti-VEGF Rx

- Avastin is agent of choice
 - Cost
 - Lowest penetrance of blood-retinal barrier
 - Experience
- Dose has not been adequately defined
 - 0.625 mg in BEAT-ROP
 - Lower doses may suppress vascular activity without inhibiting intrinsic vascular development


Type 1 ROP, Anti-VEGF Rx

- High vascular activity and posterior disease
- Too fragile to tolerate laser procedure
- Media opacity: vitreous heme, cataract, tunica vasculosa lentis
- Retina detached, anticipating vitrectomy
- Long term commitment to follow up
- Laser not available


Type 1 ROP, Anti-VEGF Rx: Follow up Protocol p Injection

- Office every 2 weeks examining leading edge of vascular development
- 70 % will reach the ora serrata
- 30% will remain non-perfused peripherally
- Fluorescein helps to define regression pattern
 - Blind ending vessels
 - Horse hair supernumerous vessels with dilation
 - Smoldering ridge with leakage
 - Traction with macular dragging, retinal detachment


Silent Brush Border



Avastin: 830 grams; 26 wk gestation, injection at 2 month and still non- perfused at 20 mo




2 months 20 months





3 months 13 months

550 gm; 22 wk gestation



2.5 months 15 months



**Type 1 ROP, Anti-VEGF Rx:
Follow up Protocol p Injection**

- Eyes that do not fully vascularize by 70 weeks post conception are not likely to ever fully vascularize
- Examination under anesthesia with fluorescein angiogram performed at the premie's first birthday
- Residual avascular retina is ablated


Judging Vascular Disease Burden

- No substitute for clinical experience
- Vascular Activity Score
 - Grading system using parameters that we typically use to judge degree of activity
- Correlates linearly with anatomic failure during PPV for ROP retinal detachment
- Guides Avastin therapy

**Vascular Activity Score:
5 categories**

1. Fetal Vessels
2. Plus
3. Shunt Width
4. Neovascularization
5. Hemorrhage or exudate

**0-2 points for each category
10 possible points**



26 weeks gestation, 34 weeks PCA
Wide ridge and 360 degrees NV &
significant plus & exudate



Relationship between vascular activity
score and anatomic outcome with
vitrectomy



Combined Anti-VEGF & Laser Ablation

- Rarely done in severe cases
 - Missed screening
 - ROP plus
 - FEVR / Norrin / I.P. mutation
 - Systemic hemangioma
 - Bone marrow diseases
 - Vasculitis
- Cannot wait for VEGF levels to drop w ablation
- Only opportunity to treat
- Prefer give Anti-VEGF first, ablation after 1-2 days

Comment: Anti-VEGF vs Laser Ablation in Type 1 ROP

- Metabolic versus Anatomic Manipulation
- Laser Ablation remains the mainstay of ROP management
- Anti-VEGF is an important adjunctive tool that has allowed excellent outcomes in eyes with previously limited prognosis, posterior and vascularly aggressive
- Proposed guidelines can not replace clinical experience and judgment, Vascular Activity Score can help
- Follow up and Fluorescein Angiography are Crucial after Anti-VEGF

CURRICULUM VITAE

A. Personal Information

Name in full Khaledcdsd Aly Tawansy, M.D.

Cellular (323) 313-5757
e-mail ktawansy@childrensretina.com; ktawansy@gmail.com

Home Address: 126 Patrician Way
Pasadena, CA 91105

Fax (323)257-3200

Place of Birth Cairo, Egypt
Citizenship U.S.A.

Languages English
Arabic
French
Medical Spanish

Office Address 1 Children's Retina Institute of California
7447 North Figueroa Street
Los Angeles, CA 90041
Phone (323)257-3300
Fax (323)257-3200

Office Address 2 Raymond Renaissance Eye Surgery Center
The Raymond Theater
125 North Raymond Avenue
Pasadena CA 91103
Phone (626) 529-3937
Fax (626) 529-3844

Office Address 3 Golden State Eye Center
1001 Tower Way
Bakersfield, CA 93309
Phone (661)327-4499
Fax (661)327-4381

Office Address 4 Beach Eye Surgery Institute
3200 North Long Beach Blvd.
Long Beach, CA 90807

B. Clinical Focus:

Retinopathy of Prematurity
Paediatric and Adult Vitreo-Retinal Surgery
Combined Anterior and Posterior Segment Surgery
Acute and Chronic Retinal Detachment
Ocular Trauma and Ultrasound
Surgical Complications

Retinal Degenerations
Proliferative Retinal Vascular Diseases
Congenital Retinal Detachment, Hereditary Vitreo-Retinopathies
Ocular Inflammatory Syndromes
Canine Retinal Detachment

C. Research Focus:

Forensic Evaluation of Child Abuse Based on Retinal Findings
Pharmacologic Management of Retinopathy of Prematurity
Minimally Invasive Protocols for Laser of Retinopathy of Prematurity
Surgical Management of Malignant Juvenile Retinoschisis
Minimally Invasive Techniques for Combined Anterior & Posterior Seg. Surgery
Canine Retinal Detachments
World Education and Surgical Care for Complex Eye Diseases

D. Education

High School	Detroit Country Day School High School Diploma, Science Concentration, Magna Cum Laude, 1983
University	Johns Hopkins University Bachelor Degree with Honors in Biomedical Engineering, 1987
Medical School	University of Michigan Medical School Doctorate of Medicine, 1991
Residencies	Residency in Internal Medicine University of California, Irvine Medical Center Marc Ofstein, M.D., Director July 1, 1991 – June 30, 1994 Residency in Ophthalmology Henry Ford Hospital and Health Sciences Center J. David Carey, M.D., Director July 1, 1994 – June 30, 1997
Clinical Fellowships	Fellowship in Vitreo-Retinal Diseases and Surgery University of British Columbia William Ross, M.D., F.R.C.S.C., Director July 1, 1997 – June 30, 1998 Fellowship in Medical Retina and Macular Diseases Vanderbilt University Medical Center J. Donald M. Gass, M.D., Preceptor (Deceased) July 1, 1998 – June 30, 1999 Fellowship in Pediatric Vitreo-Retinal Diseases and Uveitis Massachusetts Eye and Ear Infirmary and Schepens Retina Foundation Harvard Medical School Tatsuo Hirose, M.D. Director

July 1, 1999 – June 30, 2000

Research Fellowships and Extra-Mural Training

Extramural Fellowship in Pediatric Vitreo-Retinal Surgery
William Beaumont Hospital
Michael Trese, M.D., Preceptor
November 1, 1994 – June 30, 2001

Research Fellowship in Ocular Trauma and Ultrasound
Schepens Eye Research Institute
Harvard Medical School
Charles Schepens, M.D., Preceptor (Deceased)
July 1, 1999 – June 30, 2000

Ocular Pathology Clerkship
Wilmer Ophthalmologic Institute
Johns Hopkins University
W. Richard Green, M.D., Preceptor (Deceased)
1987-1991

Basic Science Course in Ophthalmology
Stanford University
Michael Marmour, M.D., Director
July 1, 1993 – August 27, 1993

Neuro-Ophthalmology Clerkship
Doheny Eye Institute, University of Southern California
Alfredo Sadun, M.D., Ph.D. and Steven Feldon, M.D., Preceptors
December 1993 – February 1994

Honors and Awards

Tau Beta Pi, National Engineering Honors Society, 1985
Young Investigator's Award, Dept. of Biomed. Eng., Johns Hopkins, 1987
Top Student Achievement, Ophthalmology and Genetics, U of Michigan, 1991
Resident of the Year, Henry Ford Hospital, 1996 – 1997
Barsky Award for Resident Research in Ophthalmology, 1997
Faculty Clinical Teacher of the Year, Vanderbilt Ophthalmology, 1998 – 1999
Faculty Surgical Instructor of the Year, Vanderbilt Ophthalmology, 2001-2002
America's Top Ophthalmologists Distinction, Consumer Reports, 2002
National Register's Who's Who Distinction, 2004
Honor Award, American Society of Retinal Specialists, 2004
Vail Vitrectomy Society 2004
Senior Honor Award, American Society of Retina Specialists, 2005
Ronald McDonald House Charities Shine Honoree, 2008
Compassionate Doctor Recognition, 2010-2013
Patient's Choice Award, (California's Favorite Doctors) 2010-2014
Patient's Choice 5th Anniversary Award, 2014
Achieving Life's Opportunities Cultural Foundation Award, 2012
Distinguished Lecturer, Vydehi Institute of Medical Sciences, 2013
Top Ten Doctors, City of Los Angeles, 2014

Licensure

California: G76762 (Active)
Michigan: 4301064042 (Expired)

British Columbia: T(E)29455 (Expired)
Tennessee: 30549 (Expired)
Massachusetts: 159724 (Expired)
DEA: BT7175525 (Active)

Board Certification

National Board of Medical Examiners, Part I, II, and III
American Board of Ophthalmology

E. Professional Background

Academic Appointments

Director of Pediatric Posterior Segment Fellowship Training Program
Children's Retina Institute of California, 2003

Assistant Professor of Ophthalmology
Loma Linda University, 2006

Visiting Assistant Professor of Pediatric Ophthalmology and Vitreo-Retinal
Surgery, University of Southern California, Keck School of Medicine;
and Doheny Eye Institute 2002

Director of Clinical Research, van Wyck-Dalany Childrens Retina Center,
Doheny Retina Institute and Children's Hospital Los Angeles, 2002

Director of Ophthalmology Residency Training Program,
Hollywood Presbyterian Medical Center, 2003

Assistant Professor of Ophthalmology and Pediatrics, Vanderbilt University,
1998

Clinical Instructor in Ophthalmology, Harvard Medical School, 1999

Fellow Scientist, Schepens Eye Research Institute, 1999

Professor of Ophthalmology, Vydehi Institute of Medical Sciences, Bangalore
India 2015

Adjunct Professor of Ophthalmology, Touro University,
California College of Osteopathic Medicine, 2016

Active Hospital Privileges

Hollywood Presbyterian Medical Center, Hollywood, CA

San Gabriel Valley Medical Center, San Gabriel, CA

Garfield Medical Center, Monterey Park, CA

Miller Children's Hospital, Long Beach CA

Long Beach Memorial Medical Center, Long Beach CA

Bakersfield Memorial Medical Center, Bakersfield, CA

Mercy Southwest Medical Center, Bakersfield, CA
Mercy Hospital Truxton Medical Center, Bakersfield CA
San Joaquin Medical Center, Bakersfield, CA
Fountain Valley Medical Center, Fountain Valley CA
Henry Mayo Medical Center, Valencia CA
Centinela Medical Center, Inglewood CA
Valley Presbyterian Medical Center, Van Nuys CA
San Antonio Community Medical Center, Upland CA
Saint Francis Medical Center, Lynwood CA
Community Regional Medical Center, Fresno CA

F. **Work Experience:** (Dates are Approximate)

Vitreo-Rerinal Surgeon, Vanderbilt University, 1998-2001
Director, Pediatric Vitreo–Retinal and Uveitis Service, Children's Hospital Los Angeles, 2002-2005
Director of Pediatric Retina and ROP Screening Program
Huntington Memorial Hospital, 2006-2015
Ophthalmology Clinic, Ocular Trauma, and ROP Services
Kern Medical Center, 2005 - 2014
Pediatric Ophthalmology and ROP Screening Program
Hollywood Presbyterian Medical Center, 2004 – 2012
Director ROP Screening Program, St. Francis, Hospital, 2006-Present
Director ROP Screening Program, San Gabriel Valley Medical Center and
Garfield Medical Center, 2005-Present
Ophthalmology Call Panel, Huntington Memorial Hospital, 2008 – Present
Ophthalmology Call Panel, Long Beach Memorial Hospital, 2015-Present
Director of ROP Screening, Valley Presbyterian Medical Medical Center, 2006-
Present
Pediatric Retina Consultant, Kaiser Permanente Sunset, Fontana, Bellflower,
Downey, Panorama City, Woodland Hills 2002-Present
National Consultant for Forensic Pediatric Retina, 2001-Present
Visiting Vitreo-Retinal Surgeon, Vydehi Institute of Medical Sciences, 2006-
Present
Director of Vitreo-Retinal Surgery, Lugene Eye Center Glendale, 2005-7

ROP Surgery Program, Children's Hospital Central California, 2008-2015

Director of Vitreo-Retinal Surgery, Bakersfield Family Medical Center, 2006-
Present

Director of ROP Screening, Bakersfield Memorial Medical Center, 2005-
Present

Director of ROP Screening, Mercy Southwest Medical Center, 2005 – Present

Director of ROP Screening, San Joaquin Medical Center, 2009-Present

Director of ROP Tele-Screening, Community Medical Center Fresno, 2012-16

Medical and Surgical Director, Children's Retina Institute, 2005 – Present

President and Director of Surgery, Raymond Renaissance Surgery Center,
2013 –Present

Director of Vitreo-Retinal Surgery, M/S Surgery Center, 2006 – Present

Director of Vitreo-Retinal Surgery, Orange County Eye Institute, 2013 – Present

Director of ROP Surgery, Centinela Hospital, 2014 – Present

Director of Canine Vitreo-Retinal Surgery, One Retina, 2006 – Present

ROP and Pediatric Retina Consultant and Surgeon, Fountain Valley Medical
Center, 2007 – Present

Ophthalmology Trauma Call, Kern County, 2005 – Present

Pediatric Ophthalmologist and Vitreo-Retinal Surgeon, Independence Medical
Group, 2005 – Present

Pediatric Ophthalmologist and Vitreo-Retinal Surgeon, Kern Family Medical
Group, 2005 - Present

G. Society Memberships

American College of Physicians, 1992

Association for Research in Vision and Ophthalmology, 1994

American Academy of Ophthalmology, 1994

Christian Eye Ministry, 1996

Canadian Ophthalmologic Society, 1997

Umbo Society, 1999

Vitreous Society, 2000

Club Vit, 2001

Los Angeles Eye Society, 2001

Pan American Academy of Ophthalmology, 2001

American Society of Retina Specialists, 2002

Vail Vitrectomy Society, 2004

Project Orbis, 2004

American Medical Association, 2005

European Retina Society, 2006

H. Bibliography

Trick GL, Vesti E, **Tawansy KA**, Skarf B, Gartner J.
Quantitative evaluation of papilledema in pseudotumor cerebri.
Invest Ophthalmol Vis Sci. 1998 Sep;39(10):1964-71.

Chang TS, **Tawansy KA**, Hay P, Holland S.
Endophthalmitis induced by Chryseomonas indologena.
Arch Ophthalmol. 1998 Nov;116(11):1533-4.

Joss KM, Lavina AM, **Tawansy KA**, Agarwal A.
Posterior repositioning of glaucoma implants for anterior segment complications.
Ophthalmology. 2001 Feb;108(2):279-84.

Desai UR, **Tawansy KA**, Joondeph BC, Schiffman RM.
Choroidal granulomas in systemic sarcoidosis.
Retina. 2001;21(1):40-7.

Nguyen QD, **Tawansy KA**, Hirose T.
Recent advances in retinopathy of prematurity.
Int Ophthalmol Clin. 2001 Fall;41(4):129-51.

Tawansy KA.

Fluorescein and indocyanine Green Angiography in Uveitis.
In Foster CS and Vitale A, eds. Uveitis Saunders, 2001

Tawansy KA.

Macular features of pediatric surgical vitreo-retinal diseases.
Ophthalmol Clin North Am. 2002 Dec:1-13.

C. Shieh, A. Agarwal, **K.A. Tawansy**, and K.M. Joos
Pars Plana Vitrectomy and Glaucoma Shunt Placement for Pediatric Aphakic Glaucoma
Invest. Ophthalmol. Vis Sci 2002 43: E-A 639

A.M. Lavina, **K.A. Tawansy**, A. Agarwal, I.U. Scott, and J.D.M. Gass
Macular Pucker Surgery: Does Pre-existing macular edema make a difference?
Invest. Ophthalmol. Vis. Sci. 2002 43: E-A 3522

Gass JD, Agarwal A, Lavina AM, and **Tawansy KA.**
Focal Inner Retinal Hemorrhages in Patients with Drusen: An Early Sign of Occult Choroidal Neovascularization and Chorioretinal Anastomosis.
Retina, 23:741-751, 2003.

K.A. Tawansy, R.R. Lakhnani, and E. de Juan, Jr.
Intraocular Triamcinolone in the Management of Zone I Retinopathy of Prematurity Refractory to Laser Ablation of the Avascular Retina
Invest. Ophthalmol. Vis. Sci. 2003 44: E-A 600

Zein G, Yu E, **Tawansy K**, Berta A, Foster CS
Neurofibromatosis type 1 associated with central nervous system lymphoma.
Ophthalmic Genet. 2004 Mar; 25(1):49-51

Tawansy K and Samuel M.

Retinopathy of Prematurity: Surgical Management in the New Millennium.

Clinical Report and Clinicians Corner. Techniques in Ophthalmology, April, 2004.

L. Jiang, H.M. Bottomley, Z. Yang, Y. Zhao, H. Lee, **K. Tawansy**, W. Tasman, J. Nathans, C. Toomes, and K. Zhang
Novel mutations in FZD4 with familial exudative vitreo-retinopathy
Invest. Ophthalmol. Vis. Sci. 2004 45: E-A 2466

A. Hayden, **K.A. Tawansy**, J.A. Gonzales, P. Patel, and M. Chung
Peripheral Retinal Non-Perfusion in the Shaken Baby Syndrome
Invest. Ophthalmol. Vis. Sci. 2004 45: E-A 271

R. Agrawal, **K. Tawansy**, and H. Lee
Surgical Management of Co-Existing Persistent Fetal Vasculature and Chorio-Retinal Coloboma
Invest. Ophthalmol. Vis. Sci. 2004 45: E-A 272

K.A. Tawansy and H. Lee
Predictors of Anatomic Failure in Surgery for Advanced Neonatal ROP Retinal Detachments
Invest. Ophthalmol. Vis. Sci. 2004 45: E-A 3535

M.A. Samuel, **K.A. Tawansy**, A.L. Murphree, N.A. Rao, R. A. Equi, T. A. Albin, and H. Lee
Clinical and Fluorescein Angiographic Characteristics of Late-Onset Retinoblastoma with Coats' Response in Children
Invest. Ophthalmol. Vis. Sci. 2004 45: E-A 3559

M. A. Hakim and **K.A. Tawansy**
Retained macular function in X-linked retinoschisis after posterior progression of bullous peripheral schisis
Invest. Ophthalmol. Vis. Sci. 2004 45: E-A 4023

H.D. Lam, **K.A. Tawansy**, M.A. Samuel, and H. Lee
Delayed Retinal Vascular Maturation and Late Onset Macular Dragging and Retinal Detachment in Neonates with Retinopathy of Prematurity
Invest. Ophthalmol. Vis. Sci. 2004 45: E-A 4027

H. Lee, **K.A. Tawansy**, and P.J. Ferrone
Proliferative Retinopathy and Tractional Retinal Detachment Associated with Chorio-Retinal Coloboma
Invest. Ophthalmol. Vis. Sci. 2004 45: E-A 2067

Simon JW, Sood S, Yoon MK, Kaw P, Zabal-Ratner J, Archer SM, Gardiner JA, Hutchinson A, Marcotty A, Noel L-P, Olsen TW, **Tawansy KA**, and Wallace DK.
Vitreotomy for Dense Vitreous Hemorrhage in Infancy.
J. Pediatr. Ophthalmol. Strabismus. 2005 Jan-Feb;42(1):18-22

Tawansy K and Moshfeghi D
Pediatric Vitreo-Retinal Surgery
Vitreo-Retinal Surgical Techniques Edited by Peyman GA, Meffert SA, Conway MD and Chou F, Martin Dunitz, 2005

Tawansy KA and Samuel MA, Management of Ocular Trauma
In Textbook of Pediatric Retina, 2005

K. Lashkari, D. Talbot, M. Ramos-Lopez, M. Shatos, J. Doherty, **K Tawansy**, and T. Hirose
Analysis of Cellular Markers Associated with Neovascular Membranes from Advancer Retinopathy of Prematurity Indicates that there is Homology with the Host Retina
Invest. Ophthalmol. Vis. Sci. 2005 46: E-A 287

D.D. Esmali, **K.A. Tawansy**, M.K. Russell, and S. Ianchulev
Delayed Lensectomy with Intra-Ocular Lens Implantation in Eyes with ROP Retinal Detachment
Invest. Ophthalmol. Vis. Sci. 2005 46: E-A 4091

H.D. Lam, **K.A. Tawansy**, and H. Lee
Wide-Field Fluorescien Angiography in the Management of Active ROP
Invest. Ophthalmol. Vis. Sci. 2005 46: E-A 4093

S. J. Young and **K.A. Tawansy**
Vitreo-Retinal Surgery for Retinal Detachment in Children with Chorio-Retinal Coloboma
Invest. Ophthalmol. Vis. Sci. 2005 46 E-A 4093.

M.E. Pons, P. Shah, H. Lee, V. Narendran, and **K.A. Tawansy**
Comparison of Threshold ROP in Southern India and Southern California
Invest. Ophthalmol. Vis. Sci. 2005 46: E-A 4103

M,A, Samuel, **K.A. Tawansy**, N. Oppenheimer, M.K. Russell, R.A.P. de Carvalho, and B. A. Kupperman
Rhegmatogenous Retinal Detachment in Neonatal Retinopathy of Prematurity
Invest. Ophthalmol. Vis. Sci. 2005 46: E-A 4104

A.A. Fawzi, M.K. Russell, K.J. Lee, K.J.B. Kelly, C. Curry, S.D. Schwartz, and **K.A. Tawansy**
Proliferative Retinopathy in Full-Term Infants with Thrombo-embolic Risk Factors
Invest. Ophthalmol. Vis. Sci. 2005 46: E-A 4127

K.A. Tawansy, R.R. Lakhanpal, and E. de Juan, Jr.
Invra-Vitreol Triamcinolone for Severe ROP Refractory to Laser Ablation: One Year Results
Invest. Ophthalmol. Vis. Sci. 2005 46: E-A 3493

J.R. Hill, B.D. Crawford, M.A. Samuel, and **K.A. Tawansy**
Evaluation of Open Globe Injuries of Children in the Last 15 Years
Invest. Ophthalmol. Vis. Sci. 2005 46: E-A 5542

R. Horn, D. Shukla, A. Rajendren, J. Baird, J. Young, E. Pearson, W. Tasman, **K. Tawansy**, K. Zhang, and American FEVR Consortium
Genetic Study of Familial Exudative Vitreo-Retinopathy
Invest. Ophthalmol. Vis. Sci. 2005 46: E-A 1795

J.A. Gonzales, **K.A. Tawansy**, A. Simon, and K. Zhang
Chorio-Retinal Coloboma in Juvenile X-Linked Retinoschisis
Invest. Ophthalmol. Vis. Sci. 2005 46: E-A 546

M.K. Russell, A. Fawzi, A. Walsh, S. Sadda, I.H. Maumenee, and **K.A. Tawansy**

Fluorescein Angiography Abnormalities in a Case Series of Leber Congenital Amaurosis
Invest. Ophthalmol. Vis Sci. 2005 46: E-A 551

Khurana RN, Samuel MA, Murphree AL, Loo RH, and **Tawansy KA**
Subfoveal Nodule in Coats' Disease
Clin. Experiment Ophthalmol. 2005 Jun;33(3):301-2.

Khurana RN, Charonis A, Samuel MA, Gupta A, and **Tawansy KA**
Intravenous foscarnet in the management of acyclovir-resistant herpes simplex virus type 2 in acute retina necrosis in children.
Med Sci Monit. 2005 Dec;11(12):CS75-8. Epub 2005 Nov 24

J. Hung, M. Evans, **K.A. Tawansy**, and N.A. Rao
Immunohistochemical Analysis of Inflammatory Cells in Pediatric Epiretinal Membranes of Diverse Causes
Invest. Ophthalmol. Vis Sci. 2006 47 E-A 5317

Ou JI, Moshfeghi DM, **Tawansy K**, and Sears JE
Macular hole in the shaken baby syndrome
Arch. Ophthalmol. 2006 Jun;124(6):913-5

A. Ingram, **K. Tawansy**, A. Ells, and P. Shah
Aggressive Diagnosis and Management of Aggressive Posterior Retinopathy of Prematurity (ROP)
Invest. Ophthalmol. Vis. Sci. 2006 47: E-A 5317

Tawansy KA, Samuel MA, Shamma M, Murphree AL
Vitreoretinal Complications of Retinoblastoma Treatment
Retina. 2006 Sep;26(7 Supplement):S47-S52.

Hill JR, Crawford BD, Lee H, **Tawansy KA**
Evaluation of Open Globe Injuries of Children in the Last 12 Years
Retina. 2006 Sep;26(7 Supplement):S65-S68.

Tawansy K
Use of Trypan Blue for Peeling of Internal Limiting Membrane
Retina Times, October, 2006

Equi R, **Tawansy K**, Samuel M, and Nguyen Q.
Familial Exudative Vitreoretinopathy.
Survey of Ophthalmology,

Shah PK, Narendran V, **Tawansy KA**, Raghuram A, Narendran K.
Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity.
Indian J Ophthalmol. 2007 Jan-Feb;55(1):75-6.

Parikh JG, **Tawansy KA**, Rao NA
Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis.
Ophthalmology. 2008 Oct;115(10):1833-6. doi: 10.1016/j.optha.2008.03.027. Epub 2008 May 21

Zhang K, Harada Y, Wei X, Shukla d, Rajendran A, **Tawansy KA**, Bedell M, Lim S, Shaw PX, HE X, Yang Z

An essential role of the cysteine-rich domain of FZD4 in Norrin/Wnt signaling and familial exudative vitreo-retinopathy
J Biol Chem. 2011 Mar 25; 286(12):1021-5

Shah PK, Narendran V, Kalpana N, **Tawansy KA**.
Anatomical and visual outcome of stages 4 and 5 retinopathy of prematurity.
Shah PK, Narendran V, Kalpana N, Tawansy KA.
Eye (Lond). 2009 Jan;23(1):176-80. Epub 2007 Aug 3.

Mintz-Hittner HA, Kennedy KA, Chuang AZ, & **BEAT-ROP Cooperative Group**
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
N Engl J Med. 2011 Feb 17; 364(7):603-15

Li q, Peng X, Flynn HW, Berrocal A, **Tawansy KA**
A 3-year old boy with poor vision and bilateral retinal detachment. JXLR
Retina 2014 May; 34(5): 1016-9

Ma J, Mehta M, Lam G, Cyr D, Ng TF, Hirose T, **Tawansy KA**, Taylor AW, Lashkari K
Influence of subretinal fluid in advanced stage retinopathy of prematurity on proangiogenic response and cell proliferation
Mol Vis 2014 Jun 21; 20:881-93

Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, **Tawansy KA**, Mintz-Hittner HA, BEAT-ROP Cooperative Group
Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial
JAMA Ophthalmol 2014 Nov 1; 132(11) 1327-33

I. Submitted Manuscripts

Tawansy KA, Hirose T, Nguyen QD.
A prospective randomized trial of low molecular weight heparin in open-sky Vitrectomy for stage V retinopathy of prematurity.

Tawansy KA, Lashkari K.
Autologous serum and peeling of the internal limiting membrane in macular hole surgery.

Tawansy KA, Hartnett ME.
Early closed vitrectomy versus late open-sky vitrectomy for advanced retinopathy of prematurity.

Tawansy KA, Donahue S, Sinatra R.
Accelerated retinopathy of prematurity and elevated systemic VEGF in premature children with large capillary hemangiomas.

Tawansy KA, Chang TS.
Submacular surgery in age-related macular degeneration for patients with type II choroidal neovascularization.

J. Presentations

Tawansy KA and Trick GL
Optical coherence tomography of the optic disc in pseudotumor cerebri

Henry Ford Hospital Alumni Meeting, June 1995

Tawansy KA and Desai UR
Granuloma of the choroids in systemic sarcoidosis
Henry Ford Hospital Alumni Meeting, June 1996

Tawansy KA and Lesser B
Hemodynamic relationships between intraocular pressure and central venous pressure
Henry Ford Hospital Alumni Meeting, June 1997

Tawansy KA, Chang TS, Maberley A, and Ma P
Sumacular surgery for type II choroidal neovascularization
University of British Columbia Alumni Meeting, 1998

Tawansy KA
Macular translocation for age-related macular degeneration
University of British Columbia Retina Meeting, February 1999

Tawansy KA
Options in the management of choroidal neovascularization
Ophthalmology Pearls Meeting, Vanderbilt University, June 1999

Tawansy KA
Choroidal neovascularization in ocular inflammatory diseases: diagnosis and management.
Combined Meeting of the American Academy of Ophthalmology and the Pan American Academy of Ophthalmology, October 1999

Tawansy KA, Nguyen QD and Hirose T
Familial exudative vitreo-retinopathy
Massachusetts Eye and Ear Infirmary Meeting on Pediatrics, May 2000

Tawansy KA
Inherited, acquired, and secondary retinoschisis
Ophthalmology Pearls Meeting, Vanderbilt University, June 2001

Tawansy KA
Surgical management of retinal detachment in children
Pan American Academy of Ophthalmology Meeting, July 2001

Tawansy KA
Juvenile retinoschisis – practical and theoretic considerations
Los Angeles Research Study Club Meeting, February 2002

Tawansy KA
Surgical options after failure of primary lens-sparing vitrectomy in retinopathy of prematurity stages IV and V
Doheny Eye Institute Alumni Meeting, June 2002

Tawansy KA, de Juan E, Lankhanpal R, Samuel MA
Small gauge instrumentation for neonatal ROP retinal detachment
American Society of Retinal Specialists Meeting, October 2002

Tawansy KA, and de Juan E

25- gauge instrumentation for the management of neonatal retinal detachment caused by acute retinopathy of prematurity
Combined Meeting of the Vitreous and Retina Societies, October 2002

Tawansy KA

Angiostatic Steroids in the Management of Severe ROP
Doheny Eye Institute Alumni Meeting, June 2003

Tawansy KA, Lankhanpal R, and de Juan E
Intravitreal Steroids in the Management of Severe ROP
American Society of Retinal Specialists Meeting, New York, August 2003

Samuel MA, **Tawansy KA**, and Murphree AL
Vitreoretinal Complications of Retinoblastoma Therapy
American Society of Retina Specialists Meeting, New York, August 2003

Tawansy KA and Hakim M
Glucose Anesthesia for Laser of Threshold ROP
American Society of Retina Specialists Meeting, New York, August 2003

Moshfeghi D, **Tawansy KA**, and Sears J
Macular Hole in the Shaken Baby Syndrome
American Society of Retina Specialists Meeting, New York, August 2003

Tawansy KA

25-gauge Vitrectomy for Neonatal ROP Detachment
4th Annual Doheny Vision Research Seminar, January 2004.

Tawansy KA

Atypical Retinal Vascular Diseases of Infants
The Research Study Club of Los Angeles, 72nd Mid-winter Clinical Conference,
January 2004.

Tawansy KA

Atypical Retinal Vascular Diseases of Infants.
Western Retina Study Club 20th Annual Meeting, Vancouver, British Columbia
February 2004

Tawansy KA

Retinopathy of Prematurity: Update on Pathogenesis and Management.
Pediatrics Grand Rounds, Long Beach Memorial Hospital, March 2004

Tawansy KA

Surgical Pearls and Pitfalls in the Management of Advanced Retinopathy of Prematurity. Anesthesia Grand Rounds, Children's Hospital Los Angeles, March 2004.

Tawansy KA, Lee H, and de Juan E

Smoldering Retinopathy of Prematurity
Vail Vitrectomy Meeting
March 2004

Tawansy KA

Principles of Pediatric Vitreo-Retinal Surgery Course
Project Orbis Mission
Kuwait City and Coimbatore, India
April 2004

Tawansy KA

Retinopathy of Prematurity: Evolution in Presentation and Management
Loma Linda University Department of Ophthalmology
Residents Research Day Meeting, June 2004

Tawansy KA

Retinal Vascular Manifestations of Retinoblastoma
USC Department of Ophthalmology
Doheny Days Meeting, June 2004

Stuart J, Samuel MA, and **Tawansy KA**

The Modern Role of Open Sky Vitrectomy in Pediatric Retinal Diseases
USC Department of Ophthalmology
Doheny Days Meeting, June 2004

Tawansy KA, de Juan E, and Lakhanpal R

Intra-Vitreous Triamcinolone for Severe ROP Refractory to Laser Ablation:
One Year Follow Up
American Society of Retina Specialists Meeting
San Diego, August 2004

Tawansy KA

Management of ROP: Breakfast with the Masters
American Society of Retina Specialists Meeting
San Diego, August 2004

Shammas MC, Samuel MA, Jubran R, **Tawansy KA**, and Murphree AL

Late Recurrence of Intraocular Retinoblastoma
American Society of Retina Specialists Meeting
San Diego, August 2004

Gonzales JA, **Tawansy KA**, Hayden A, Patel P, Chung M

Peripheral Retinal Non-Perfusion and Tractional Retinal Detachment in the
Shaken Baby Syndrome
American Society of Retina Specialists Meeting
San Diego, August 2004

Lam HH, **Tawansy KA**, Lee H, Samuel MA, Novack RL, and Bryan JS

Smoldering ROP: Late Onset Neonatal Retinal Detachment
American Society of Retina Specialists Meeting
San Diego, August 2004

Samuel MA and **Tawansy KA**

The Modern Role of Scleral Buckle in ROP Retinal Detachment
American Society of Retina Specialists Meeting
San Diego, August 2004

Lee H, **Tawansy KA**, Chung M, and Stout JT

Predictors of Anatomic Failure in ROP Retinal Detachment
American Society of Retina Specialists Meeting
San Diego, August 2004

Russell M, **Tawansy KA** Ianchelev S

Delayed Lensectomy with IOL Implantation in Neonates with ROP
American Society of Retina Specialists Meeting
San Diego, August 2004

Rahul NK, Charonis A, Samuel MA, Gupta A, and **Tawansy KA**
Intravenous Foscarnet in the Management of Acyclovir Resistant Herpes
Simplex Virus Type 2 in Acute Retinal Necrosis in Children
American Society of Retinal Specialists Meeting
San Diego, August 2004

Pons M, Samuel MA, **Tawansy KA**, Murphree AL
Recession Patterns in Retinoblastoma after Chemotherapy and Local
Consolidation
American Society of Retina Specialists Meeting
San Diego, August 2004

Agrawal RN, **Tawansy KA**, and Lee H
Clinical Features and Surgical Management of Co-Existing Persistent Fetal
Vasculature and Chorio-Retinal Coloboma
American Society of Retina Specialists Meeting
San Diego, August 2004

Margolis R, Murphree AL, Evans M, **Tawansy KA**, and Rao N
Diagnosis of Iris Neovascularization in Retinoblastoma by Fluorescein
Angiogram
American Society of Retina Specialists Meeting
San Diego, August 2004

Tawansy KA and Takeshita B
A Team Approach of Early Intervention for Children with Vision Impairment
Southern California Network Conference
Santa Ana, October 2004

Tawansy KA
Retinal Disorders of Children
Foundation for the Junior Blind Annual Meeting
Los Angeles, October 2004

Tawansy KA
Techniques in ROP Retinal Detachment Surgery
JJ Bausch Symposia Series
American Academy of Ophthalmology Annual Meeting
New Orleans, October 2004

Lee TC, Chaum E, **Tawansy KA**, Mukai S, Wilson M, Ober M, Hayashi N,
Murphree AL, Haik B, Abramson D
Factors and Management of Vitreous Hemorrhage in Patients with
Retinoblastoma
American Academy of Ophthalmology Annual Meeting
New Orleans, October 2004

Tawansy KA
Retinopathy of Prematurity: Practical Pearls
White Memorial Hospital Grand Rounds
Los Angeles, November 2004

Tawansy KA, Samuel MA, Murphree AL, Rao N, See R
Retinal Vascular Manifestations of Retinoblastoma
Association of Pediatric Retina Specialists Meeting
Duck Key, January 2005

Tawansy KA

Pediatric Retina Symposium
Mexico City Institute of Ophthalmology Annual Meeting
Mexico City, February 2005

Tawansy KA, Samuel MA, Murphree AL, Rao N, See R
Retinal Vascular Manifestations of Ischemic Retinoblastoma
Pan-American Association of Ophthalmology Annual Meeting
Santiago, March 2005

Tawansy KA, Pons M, Lee H, Shah P, Narendran V
Comparison of Threshold ROP in Southern California and Southern India
Pan-American Association of Ophthalmology Annual Meeting
Santiago, March 2005

Tawansy KA, Gonzales J, Hayden A, Evans M
Retinal Non-Perfusion in the Shaken Baby Syndrome
Pan-American Association of Ophthalmology Annual Meeting
Santiago, March 2005

Tawansy KA

Surgical Management of Malignant Infantile Retinoschisis
Loma Linda University Alumni Day Meeting, April 2006

Tawansy KA

Bullous Infantile Retinoschisis: Practical Considerations
Club Vit Annual Meeting
Whistler, Canada July 2006

Tawansy KA

Delayed Retinal Vascular Maturation in Preemies with CNS Disease
American Academy of Ophthalmology Meeting
Chicago, 2007

Tawansy KA

Bevacizumab in the Management of Advanced ROP
University of Ottawa Grand Rounds
Ottawa, Canada 2009

Tawansy KA and Minz-Hittner HA

BEAT-ROP Study Protocol and Preliminary Outcomes
World Symposium on ROP
New Delhi, India, 2009

Tawansy KA

BEAT-ROP Study Update
Indian Vitreo-Retinal Society Meeting
Nepal, 2009

Tawansy KA and Hoffman AR

Retinopathy of Prematurity in Kittens
Western Retina Society Meeting
San Diego, 2009

Tawansy KA

Anti-VEGF Therapy for Posterior ROP

Taiwanese Vitreo-Retinal Society Meeting
Taiwan, 2009

Tawansy KA
Smoldering Retinopathy of Prematurity
American Society of Retina Specialists Meeting
Palm Springs, 2009

Tawansy KA and Merkur A
Exudative Juvenile Retinoschisis: A new Phenotype
American Society of Retinal Specialists Meeting
Palm Springs, 2009

Tawansy KA and Matti N
High dose bevacizumab for the management of advanced pediatric proliferative
retinopathies
American Society of Retina Specialists Meeting
Vancouver, CA 2010

Tawansy KA and Mintz-Hittner HA
Beat-ROP Study Results
American Society of Retina Specialists Annual Meeting
Vancouver, CA 2010

Tawansy KA and Albiani D
The role of scleral buckle in the management of chorio-retinal coloboma
detachments
American Society of Retina Specialists Annual Meeting
Vancouver, 2010

Tawansy KA and Kherani A
Vascular Regression Patterns after Bevacizumab Therapy for Posterior ROP
American Society of Retina Specialists Annual Meeting
Vancouver, CA 2010

Tawansy KA
Type 1 ROP: Current Management and Practical Considerations
Euretina 13th Annual Congress
Hamburg, Germany
September, 2013

Tawansy KA
Management of Advanced Pediatric Retinal Diseases
Skill Matrix International Conference
Bridging the Gap between Medicine and Education
Bangalore, India
November, 2013

Tawansy KA
Retinopathy of Prematurity: Update on Diagnosis and Management
Centinela Hospital Rounds
March, 2014

Tawansy KA
Center for the Partially Sighted Symposium
Bill Takeshita Achievement Award

Skirball Center
September, 2014

Tawansy KA

Avastin versus Laser in the Management of Type 1 ROP
Euretina 14th Annual Congress
London
September, 2014

Tawansy KA

Evaluation of Child Abuse based on Retinal Findings
National Child Abuse Resource Center Conference
Los Vegas
October, 2014

K. Fellows Trained

Juan Astruc, M.D., 2000-2001
Richmond Eye and Ear Institute
Richmond, Virginia

Adrian M. Lavina, M.D., 2001-2002
Private Practice
Palm Beach Gardens, Florida

Hatem Kobtan, M.D., F.R.C.S., 2003-2003
University of Cairo
Faculty of Ophthalmology
Cairo, Egypt

Michael A. Samuel, M.D., 2003-2004
Retina Institute of California
Pasadena, CA

Matt Russell, M.D., F.R.C.S.C., 2004-5
University of New Zealand
Division of Vitreo-Retinal Surgery

Mauricio Pons, M.D., 2004-5
University of Virginia

Parag Shah, MBBS, 2006
Faculty, Division of Vitreo-Retinal Surgery
Arrivand Eye Hospital
Coimbatore, India

Jennifer Hung, M.D., 2005-6
University of Southern California School of Medicine
Los Angeles, CA

Mohamed Alomran, M.D., M.S., 2005-6
Division of Vitreo-Retinal Surgery
University of Bahrain

Natalia Matti, M.D, 2007-8
Pediatric Vitreo-Retinal Surgeon
Tijuana and Northern Mexico

David Albiani, M.D., 2009
Faculty of Medicine
Department of Ophthalmology
University of British Columbia
Directory, Vitreo-Retinal Fellowship
Vancouver, CA

Andrew Murker, M.D., 2009
Department of Ophthalmology
University of British Columbia
Vancouver, BC

Enrique Ariza, M.D., 2009-2010
Pediatric and Adult Vitreo-Retinal Surgeon
Mexico City, Mexico

Eugene Ing, M.D.
Pediatric and Adult Vitreo-Retinal Surgeon
Honolulu, Hawaii

L. Extracurricular Interests

Lacrosse, Bicycling, Swimming, Hiking, Skiing
Creative Writing
Jazz and Rock Music
Missionary Medical Projects.

M. References

William Ross, M.D., F.R.C.S.C.
Professor of Ophthalmology
Former Director of Vitreo-Retinal Fellowship Program
University of British Columbia
805 West Broadway, Suite: 400
Vancouver, BC V5Z-1K1
(604) 874-0404

Eugene de Juan, Jr., M.D.
Professor of Ophthalmology and Vitreo-Retinal Surgery
University of California San Francisco Medical Center
400 Parnassus Avenue, 7th Floor, Suite A750, Box 0344
San Francisco, CA 94143
(415) 353-2402

Kameron Lashkari, M.D.
Schepens Eye Research Institute
1155 Centre Street Suite 4349
Jamaica Plain, MA 02130
(617) 469-2162

Narsing Rao, M.D.
Professor of Ophthalmology and Pathology
University of Southern California Eye Institute

1450 San Pable Street
Doheny Vision Research Center
Los Angeles, CA 90033
(323) 442-6645

Jennifer Dunbar, M.D.

Associate Professor of Pediatric Ophthalmology
Loma Linda University Medical Center
11370 Anderson Street, Suite 1800
Loma Linda, CA 92354
(909) 558-2154

Michelle Britt, M.D.

Staff Ophthalmologist
Pediatric Ophthalmology and Strabismus
Kaiser Permanente Medical Center, Baldwin Park
(626) 372-1889

David Sami, M.D.

CHOC PSF Ophthalmology
392 S Glassell, Ste 100
Orange, CA 92866
(714) 289-2389

Sharon Spooner, M.D.

Pediatric Ophthalmologist
2222 Santa Monica Ste 401
Santa Monica, CA 90404
(310) 453-0471

Michael Miller, M.D.

Past Director of Ophthalmology,
Huntington Memorial Hospital
800 Fairmont Avenue, Suite 101
Pasadena, CA 91105

Joseph Davidson, M.D.

Director of Ophthalmology
Huntington Memorial Hospital
800 Fairmont Avenue, Suite 219
Pasadena, CA 91105

Adria Winter, M.D.

Department of Emergency Medicine
Kern Medical Center
1700 Mount Vernon Avenue
Bakersfield, CA 93306

H. John Shammas, M.D.

Professor of Ophthalmology, USC
Shammas Eye Medical Center
3510 Martin Luther King Jr. Blvd
Lynwood, CA 90262
310-638-9391

Bill Takeshita, O.D., F.A.A.O., F.C.O.V.D.

Chief of Optometry
Center for the Partially Sighted
7462 N. Figueroa Blvd. #103
Los Angeles, CA 90041
(310) 988 – 1970

Amod, Moosa, M.D.
Neonatal & Perinatal Pediatrician
Former Medical Staff Director
St. Francis Medical Center
3630 E Imperial Hwy,
Lynwood, CA 90262
(310) 900-2004

Ricardo Liberman, M.D.
Director Emeritus of Neonatology
Huntington Memorial Hospital
100 W California Blvd,
Pasadena, CA 91105
(626) 397-3826

Hosein Mohammadi, M.D.
Ophthalmologist
Director, Central Valley Eye Care
5000 Physicians Blvd,
Bakersfield, CA 93301
(661) 846-4985

Richard Meidell, M.D.
Pediatrician
Garfield Medical Center
525 N Garfield Ave,
Monterey Park, CA 91754
(626) 573-2222

Sue Parker-Strafaci
Director of Child Development
The Braille Institute
741 N Vermont Ave,
Los Angeles, CA 90029
(323) 663-1111

Jane Kelly, M.D.
Pediatric Ophthalmologist
Rady Children's Hospital
3030 Children's Way
San Diego, CA 92123

Veronique Jotterand, M.D.
Chief of Staff, Miller Children's Hospital
Pediatric Ophthalmologist
2865 Atlantic Ave #212
Long Beach, CA 90806
(562) 988-2020

George Alexandrakis, M.D.
Ophthalmologist
Bakersfield, CA 93301
(661) 323-4200